Daiichinkyo Co (STU:D4S) 3-Year Revenue Growth Rate : 19.00% (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co 3-Year Revenue Growth Rate?

Daiichinkyo Co's Revenue per Share for the three months ended in Mar. 2024 was €1.37.

During the past 12 months, Daiichinkyo Co's average Revenue per Share Growth Rate was 25.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 19.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 11.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was 5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Daiichinkyo Co was 19.00% per year. The lowest was -3.60% per year. And the median was 1.70% per year.

Competitive Comparison of Daiichinkyo Co's 3-Year Revenue Growth Rate

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daiichinkyo Co's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's 3-Year Revenue Growth Rate falls into.

Daiichinkyo Co 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Daiichinkyo Co (STU:D4S) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Daiichinkyo Co 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Daiichinkyo Co (STU:D4S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (STU:D4S) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

DSNKY:USA DSKYF:USA 4568:Japan

Address

3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426

Website

https://www.daiichisankyo.com

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co (STU:D4S) Headlines

No Headlines